The use of Imatinib mesylate (Glivec) in Nigerian patients with chronic myeloid leukemia.

Citation:
Kuliya-Gwarzo A, Ibegbulam OG, Mamman A, Raji AA, Akingbola TS, Mabayoje VO, Ocheni S, Tanko Y, Amusu OA, Akinyanju OO, Ndakotsu MA, Kassim DO, Arewa OP, Bolarinwa RAA, Olaniyi JA, Okocha CE, Akinola NO, Bamgbade OO, Adediran IA, Salawu L, Faluyi JO, Oyekunle AA, Okanny CC, Akanmu S, Halim DNK, Bazuaye GN, Enosolease ME, Nwauche CA, Ogbe OP, Wakama TT, Durosinmi MA. "The use of Imatinib mesylate (Glivec) in Nigerian patients with chronic myeloid leukemia." Cellular Therapy and Transplantation. 2008;1:10.3205/ctt-2008-en-000027.01. copy at www.tinyurl.com/hvz8hv9

Abstract:

Objectives: To assess response and toxicity to Imatinib mesylate (Glivec) in Nigerian Patients with chronic myeloid leukemia. Methods: From August 2003 to August 2007, 98 consecutive, consenting patients, 56 (57%) males and 42 (43%) females, median age 36 years (range, 11-65 years) diagnosed with CML, irrespective of disease phase received Imatinib at a dose of 300-600mg/day at the OAU Teaching Hospitals, Nigeria. Response to therapy was assessed by clinical, haematological and cytogenetic parameters. Blood counts were checked every two weeks in the first three months of therapy. Chromosome analysis was repeated sixth monthly. Overall survival (OS) and frequency of complete or major cytogenetic remission (CCR/MCR) were evaluated. Results: Complete haematologic remission was achieved in 64% and 83% of patients at one and three months, respectively. With a median follow-up of 25 months, the rates of CCR and MCR were 59% and 35% respectively. At 12 months of follow-up, OS and progression- free survival (PFS) were 96% and 91%, respectively. Achievement of CR at six months was associated with significantly better survival (p = 0.043).Conclusions: Compared to treatment outcome with conventional chemotherapy and alpha interferon, as previously used in Nigeria, the results obtained with this regimen has established Imatinib as the first-line treatment strategy in patients with CML, as it is in other populations, with minimal morbidity.

Notes:

n/a